心律调节器市场：规模、细分市场、份额、法规、报销、程序、到 2033 年的预测

病态窦房结综合征，也称为窦房结功能障碍，是一种导致多种心律不整的疾病。 病态窦房结症候群的主要原因是衝动产生受损、传导异常或窦房结功能受损。 心臟传导阻滞是由于房室结或希氏-浦肯野系统的传导系统异常而导致从心房到心室的电传导受阻或延迟。 心臟传导阻滞依其严重程度分为一级、二级或三级。 病态窦房结症候群和心臟传导阻滞可以用抗心律不整药物治疗，但更明确的治疗方法是植入心臟节律器，这有助于维持规律的心跳。 老年患者对人工心律调节器的耐受性良好。 建议使用心房起搏器来治疗除慢性心房颤动患者以外的所有患者的病态窦房结症候群和心臟传导阻滞。

本报告深入探讨了全球起搏器市场，包括竞争格局、SWOT 分析、到 2033 年的市场预测、COVID-19 的影响、区域和国家趋势等。

目录

心律调节器目前市场及竞争状况

• 对主要产业趋势的见解
• 按细分市场划分的起搏器市场总收入以及 2015 年至 2033 年的市场前景
• 按细分市场划分的手术总数、单位数量、平均售价和市场价值的详细数据

全球、区域与国家见解

• 起搏器市场的SWOT分析
• 起搏器市场的竞争动态洞察与趋势
• 各国医疗保健系统概览
• 按国家/地区划分的报销政策
• 各国医疗科技的监管状况

Abstract

Pacemakers Market Size by Segments, Share, Regulatory, Reimbursement, Procedures and Forecast to 2033 is built to visualize quantitative market trends within Cardiovascular Devices therapeutic area.

The model discusses in detail the impact of COVID-19 on Pacemakers market for the year 2020 and beyond. Sick sinus syndrome also known sinus node dysfunction is a number of conditions causing arrhythmias. The major causes of sick sinus syndrome can be the failure of impulse generation, abnormal conduction or sinus node degradation. Heart block is an interruption or delay of electrical conduction from the atria to the ventricles due to conduction system abnormalities in the AV node or the His-Purkinje system. Heart block is classified into first degree, second degree and third degree heart block based on its severity. Sick sinus syndrome and heart block can be treated with antiarrhythmic medicines but a more reliable treatment is implantation of a cardiac pacemaker which helps in maintaining a regular heartbeat. Artificial pacemakers are well tolerated in elderly patients. Atrial based pacemakers are recommended for treatment of sick sinus syndrome and heart block in all the patients except those with chronic atrial fibrillation.

Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.

Key Inclusions of the market model are -

Currently marketed Pacemakers market and evolving competitive landscape -

• Insightful review of the key industry trends.
• Annualized total Pacemakers market revenue by segment and market outlooks from 2015-2033.
• Granular data on total procedures, units, average selling prices and market values by segment.

Global, Regional and Country level market specific insights -

• Qualitative market specific information is available with global trends further broken down into regional trends. In addition GlobalData analysts provide unique country specific insights on the market.
• SWOT analysis for Pacemakers market.
• Competitive dynamics insights and trends provided Pacemakers market.

Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.

• Country specific overview of the healthcare system.
• Country specific reimbursement policies.
• Country specific medtech regulatory landscape.

Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.

Companies covered: Medtronic Plc, Biotronik SE & Co KG, Abbott Laboratories, Boston Scientific Corp, MicroPort Scientific Corp, and Others.

Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.

Scope

This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -

• CMO executives who must have deep understanding of the Pacemakers marketplace to make strategic planning and investment decisions.
• Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
• Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.

Reasons to Buy

The model will enable you to -

• Understand the impact of COVID-19 on Pacemakers market.
• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving Pacemakers market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Pacemakers market in the future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Track device sales in the global and country-specific Pacemakers market from 2015-2033.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Table of Contents

Not Applicable

List of Tables

Not Applicable

List of Figures

Not Applicable